Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

Exploring the use of exosomal plasma gelsolin as a biomarker for early ovarian cancer diagnosis

FY 2021-22

Summary
Ovarian cancer (OVCA) is the most lethal gynecological disease. Unfortunately, less than half of those diagnosed with OVCA will live to see the next 5 years. One of the reasons for this low survival rate is because OVCA is not usually diagnosed until advanced stages of cancer. The biomarker currently used for OVCA diagnosis, CA125, is not ideal for early diagnosis because it is inconsistently elevated in early stages. Thus, a more reliable and robust biomarker is needed to diagnose OVCA earlier. We propose plasma gelsolin (pGSN), an actin binding protein in the blood, as a biomarker for early OVCA diagnosis. This protein is secreted via small extracellular vesicles (exosomes) from OVCA cells and is elevated in stage 1 of the disease. We therefore propose that exosomal pGSN will be an even more sensitive biomarker for early diagnosis. In this study, we will measure total pGSN and exosomal pGSN in plasma samples from OVCA patients. The results will be related to patients clinical information such as FIGO (International Federation of Gynecology and Obstetrics) stage, OVCA histopathological subtype, chemoresponsiveness, and patient survival, allowing us to determine pGSN performance as a biomarker of early-stage OVCA diagnosis. When patients are diagnosed with OVCA in stage 1, the 5-year survival rate is around 90%, highlighting the importance of catching this disease as early as possible. This study will provide evidence of pGSN as a biomarker for early OVCA diagnosis, thus improving patient survival.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
467118
Name
Gerber Emma
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Exploring the use of exosomal plasma gelsolin as a biomarker for early ovarian cancer diagnosis
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biomarkers; Chemoresistance; Early Diagnosis; Exosomes; Figo Stage; Histopathological Subtypes; Ovarian Cancer; Patient Survival; Plasma Gelsolin; Small Extracellular Vesicles
Abstract
Ovarian cancer (OVCA) is the most lethal gynecological disease. Unfortunately, less than half of those diagnosed with OVCA will live to see the next 5 years. One of the reasons for this low survival rate is because OVCA is not usually diagnosed until advanced stages of cancer. The biomarker currently used for OVCA diagnosis, CA125, is not ideal for early diagnosis because it is inconsistently elevated in early stages. Thus, a more reliable and robust biomarker is needed to diagnose OVCA earlier. We propose plasma gelsolin (pGSN), an actin binding protein in the blood, as a biomarker for early OVCA diagnosis. This protein is secreted via small extracellular vesicles (exosomes) from OVCA cells and is elevated in stage 1 of the disease. We therefore propose that exosomal pGSN will be an even more sensitive biomarker for early diagnosis. In this study, we will measure total pGSN and exosomal pGSN in plasma samples from OVCA patients. The results will be related to patients clinical information such as FIGO (International Federation of Gynecology and Obstetrics) stage, OVCA histopathological subtype, chemoresponsiveness, and patient survival, allowing us to determine pGSN performance as a biomarker of early-stage OVCA diagnosis. When patients are diagnosed with OVCA in stage 1, the 5-year survival rate is around 90%, highlighting the importance of catching this disease as early as possible. This study will provide evidence of pGSN as a biomarker for early OVCA diagnosis, thus improving patient survival.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gerber, Emma
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~